Indivior PLC (NASDAQ:INDV) Receives $39.33 Consensus Target Price from Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $39.3333.

INDV has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th.

Insiders Place Their Bets

In other news, Director Stuart A. Kingsley acquired 940 shares of Indivior stock in a transaction that occurred on Friday, March 6th. The shares were bought at an average cost of $31.86 per share, with a total value of $29,948.40. Following the transaction, the director directly owned 5,582 shares of the company’s stock, valued at $177,842.52. This trade represents a 20.25% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.74% of the stock is owned by company insiders.

Institutional Trading of Indivior

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INDV. Goldman Sachs Group Inc. raised its position in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the period. Jane Street Group LLC raised its position in Indivior by 2,597.9% in the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after purchasing an additional 958,132 shares during the period. JPMorgan Chase & Co. raised its position in Indivior by 669.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock worth $5,769,000 after purchasing an additional 340,498 shares during the period. Prudential Financial Inc. purchased a new stake in Indivior in the 2nd quarter worth about $207,000. Finally, Walleye Capital LLC purchased a new stake in Indivior in the 2nd quarter worth about $594,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Stock Performance

Shares of NASDAQ:INDV opened at $37.53 on Monday. Indivior has a 12 month low of $11.08 and a 12 month high of $41.00. The company has a 50-day moving average price of $33.39 and a 200 day moving average price of $33.74. The company has a market cap of $4.58 billion, a price-to-earnings ratio of 19.25 and a beta of 0.90.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The firm had revenue of $317.00 million during the quarter. As a group, equities analysts forecast that Indivior will post 3.35 EPS for the current year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.